A Phase 3, Multicenter, Open Label Study to Evaluate the Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis
Phase of Trial: Phase III
Latest Information Update: 02 May 2017
At a glance
- Drugs Tazarotene/ulobetasol (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Registrational
- Sponsors Valeant Pharmaceuticals International
- 26 Apr 2017 Status changed from active, no longer recruiting to completed.
- 15 Aug 2016 Planned End Date changed from 1 Sep 2016 to 1 Nov 2017.
- 15 Aug 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Aug 2017.